Evidence map›Paper›PMID 38864129›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2024

[Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study].

Tianjing Zhou, Qiuping Liu, Minglu Zhang, Xiaofei Liu, Jiali Kang, Peng Shen, Hongbo Lin, Xun Tang, Pei Gao

Abstract readComparative StudyEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tianjing ZhouDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Qiuping LiuDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Minglu ZhangDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Xiaofei LiuDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Jiali KangDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Peng ShenYinzhou District Center for Disease Control and Prevention, Ningbo 315101, Zhejiang, China.
Hongbo LinYinzhou District Center for Disease Control and Prevention, Ningbo 315101, Zhejiang, China.
Xun TangDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Pei GaoDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the health benefits and intervention efficiency of different strategies of initiating antihypertensive therapy for the primary prevention of cardiovascular diseases in a community-based Chinese population from the Chinese electronic health records research in Yinzhou (CHERRY) study.

methodsA decision-analytic Markov model was used to simulate and compare different antihypertensive initiation strategies, including: Strategy 1, initiation of antihypertensive therapy for Chinese adults with systolic blood pressure (SBP) ≥140 mmHg (

resultsA total of 213 987 Chinese adults aged 35-79 years without cardiovascular diseases were included. Compared with strategy 1, the number of cardiovascular events that could be prevented in strategy 2 increased by 666 (95%

conclusionWhen initiating antihypertensive therapy in an economically developed area of China, the strategy combined with cardiovascular risk assessment is more efficient than those purely based on the SBP threshold. The cardiovascular risk assessment strategy with different SBP thresholds is suggested to balance health benefits and intervention efficiency in diverse populations.

Indexed as

Antihypertensive AgentsCardiovascular DiseasesHypertensionMarkov ChainsPrimary PreventionAdultAgedBlood PressureChinaDecision Support TechniquesFemaleHumansMaleMiddle AgedQuality-Adjusted Life YearsAntihypertensive AgentsBlood pressure managementCardiovascular diseasesMarkov modelPrimary prevention

Identifiers

PMID38864129
PMCPMC11167542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.